Antiplatelet therapy with or without PPIs for the secondary prevention of cardiovascular diseases in patients at high risk of upper gastrointestinal bleeding: A systematic review and meta-analysis

Wu,Wenfa; Liu,Jia; Yu,Huiwen; Jiang,Zuofeng

doi:10.3892/etm.2020.8657

Antiplatelet therapy with or without PPIs for the secondary prevention of cardiovascular diseases in patients at high risk of upper gastrointestinal bleeding: A systematic review and meta-analysis

Authors:
- Wenfa Wu
- Jia Liu
- Huiwen Yu
- Zuofeng Jiang
View Affiliations

Affiliations: Department of General Practice, Guangzhou Red Cross Hospital, Medical College, Jinan University, Guangzhou, Guangdong 510220, P.R. China, Department of VIP Medical Center, the Third Affiliated Hospital, Medical College, Sun Yat-sen University, Guangzhou, Guangdong 510220, P.R. China
Published online on: April 9, 2020 https://doi.org/10.3892/etm.2020.8657
Pages: 3595-3603
Copyright: © Wu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Recurrent upper gastrointestinal (UGI) and cardiovascular (CV) events of the three antiplatelet therapies in patients with cardiovascular diseases (CVD) were compared. Studies published in the PubMed, Embase, and Cochrane Central Register of Controlled Trials electronic databases that compared differences in adverse outcomes associated with the three antiplatelet therapies were reviewed. Five studies with a total number of 7,399 patients were included. No significant differences were found in the incidence of recurrent UGI events among the three antiplatelet therapies. However, in the aspirin-induced ulcer bleeding subgroups, aspirin plus proton pump inhibitors (PPIs) was associated with a significantly lower risk of recurrent UGI events (OR: 0.06, 95% CI: 0.01-0.32; z=3.30 and P=0.001) and UGI bleeding (OR: 0.06, 95% CI: 0.01-0.34; z=3.24 and P=0.001) compared to clopidogrel alone. Both aspirin plus PPIs (OR: 2.12, 95% CI: 1.58-2.84; z=5.00 and P<0.01) and clopidogrel plus PPIs (OR: 2.57, 95% CI: 1.89-3.51; z=5.97 and P<0.01) were related to a comparatively higher risk of recurrent CV events when compared to clopidogrel alone. In patients at high UGI bleeding risk (regardless of whether it was aspirin-induced) and under treatment of single antiplatelet therapy, aspirin plus PPIs should be considered as the first choice for UGI protection rather than clopidogrel alone and clopidogrel plus PPIs. However, in terms of CV protection, clopidogrel alone appears to be superior in reducing CV risk, while clopidogrel plus PPIs may relate to an increased CV risk due to the potential drug-drug interaction.

View Figures

View References

1	Farrell B, Godwin J, Richards S and Warlow C: UK-TIA Study Group: The United Kingdom transient ischaemic attack (UK-TIA) aspirin trial: Final results. J Neurol Neurosurg Psychiatry. 54:1044–1054. 1991.PubMed/NCBI View Article : Google Scholar
2	CAPRIE Steering Committee: A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 348: 1329-1339, 1996.
3	Braunwald E, Antman EM, Beasley JW, Califf RM, Cheitlin MD, Hochman JS, Jones RH, Kereiakes D, Kupersmith J, Levin TN, Pepine CJ, Schaeffer JW, Smith EE III, Steward DE and Theroux P: ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Uns Table Angina). Circulation. 106:1893–1900. 2002.PubMed/NCBI View Article : Google Scholar
4	Ng FH, Wong SY, Chang CM, Chen WH, Kng C, Lanas AI and Wong BC: High incidence of clopidogrel-associated gastrointestinal bleeding in patients with previous peptic ulcer disease. Aliment Pharmacol Ther. 18:443–449. 2003.PubMed/NCBI View Article : Google Scholar
5	Lai KC, Lam SK, Chu KM, Wong BC, Hui WM, Hu WH, Lau GK, Wong WM, Yuen MF, Chan AO, et al: Lansoprazole for the prevention of recurrences of ulcer complications from long-term low-dose aspirin use. N Engl J Med. 346:2033–2038. 2002.PubMed/NCBI View Article : Google Scholar
6	Chan FK, Ching JY, Hung LC, Wong VW, Leung VK, Kung NN, Hui AJ, Wu JC, Leung WK, Lee VW, et al: Clopidogrel versus aspirin and esomeprazole to prevent recurrent ulcer bleeding. N Engl J Med. 352:238–244. 2005.PubMed/NCBI View Article : Google Scholar
7	Lai KC, Chu KM, Hui WM, Wong BC, Hung WK, Loo CK, Hu WH, Chan AO, Kwok KF, Fung TT, et al: Esomeprazole with aspirin versus clopidogrel for prevention of recurrent gastrointestinal ulcer complications. Clin Gastroenterol Hepatol. 4:860–865. 2006.PubMed/NCBI View Article : Google Scholar
8	Tsai YW, Wen YW, Huang WF, Chen PF, Kuo KN and Hsiao FY: Cardiovascular and gastrointestinal events of three antiplatelet therapies: Clopidogrel, clopidogrel plus proton-pump inhibitors, and aspirin plus proton-pump inhibitors in patients with previous gastrointestinal bleeding. J Gastroenterol. 46:39–45. 2011.PubMed/NCBI View Article : Google Scholar
9	Hsu PI, Lai KH and Liu CP: Esomeprazole with clopidogrel reduces peptic ulcer recurrence, compared with clopidogrel alone, in patients with atherosclerosis. Gastroenterology. 140:791–798. 2011.PubMed/NCBI View Article : Google Scholar
10	Hsiao FY, Tsai YW, Huang WF, Wen YW, Chen PF, Chang PY and Kuo KN: A comparison of aspirin and clopidogrel with or without proton pump inhibitors for the secondary prevention of cardiovascular events in patients at high risk for gastrointestinal bleeding. Clin Ther. 31:2038–2047. 2009.PubMed/NCBI View Article : Google Scholar
11	Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP, Clarke M, Devereaux PJ, Kleijnen J and Moher D: The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: Explanation and elaboration. BMJ. 339 (jul21 1)(b2700)2009.PubMed/NCBI View Article : Google Scholar
12	Sterne JAC, Higgins JPT and Reeves BC: A Cochrane Risk of Bias Assessment Tool: for Non-Randomized Studies of Interventions (ACROBAT-NRSI). Version 1.0.0, September 24, 2014. Retrieved from http://www.riskofbias.info. Accessed: May 21, 2015.
13	Higgins JPT, Thompson SG, Deeks JJ and Altman DG: Measuring inconsistency in meta-analyses. BMJ. 327:557–560. 2003.PubMed/NCBI View Article : Google Scholar
14	Ma L, Elliott SN, Cirino G, Buret A, Ignarro LJ and Wallace JL: Platelets modulate gastric ulcer healing: Role of endostatin and vascular endothelial growth factor release. Proc Natl Acad Sci USA. 98:6470–6475. 2001.PubMed/NCBI View Article : Google Scholar
15	Ng FH, Wong BC, Wong SY, Chen WH and Chang CM: Clopidogrel plus omeprazole compared with aspirin plus omeprazole for aspirin-induced symptomatic peptic ulcers/erosions with low to moderate bleeding/re-bleeding risk - a single-blind, randomized controlled study. Aliment Pharmacol Ther. 19:359–365. 2004.PubMed/NCBI View Article : Google Scholar
16	Hass WK, Easton JD, Adams HP Jr, Pryse-Phillips W, Molony BA, Anderson S and Kamm B: Ticlopidine Aspirin Stroke Study Group: A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. N Engl J Med. 321:501–507. 1989.PubMed/NCBI View Article : Google Scholar
17	Savi P, Bernat A, Dumas A, Aït-Chek L and Herbert JM: Effect of aspirin and clopidogrel on platelet-dependent tissue factor expression in endothelial cells. Thromb Res. 73:117–124. 1994.PubMed/NCBI View Article : Google Scholar
18	Kim KA, Park PW, Hong SJ and Park JY: The effect of CYP2C19 polymorphism on the pharmacokinetics and pharmacodynamics of clopidogrel: A possible mechanism for clopidogrel resistance. Clin Pharmacol Ther. 84:236–242. 2008.PubMed/NCBI View Article : Google Scholar
19	Sibbing D, Morath T, Stegherr J, Braun S, Vogt W, Hadamitzky M, Schömig A, Kastrati A and von Beckerath N: Impact of proton pump inhibitors on the antiplatelet effects of clopidogrel. Thromb Haemost. 101:714–719. 2009.PubMed/NCBI
20	Gilard M, Arnaud B, Cornily JC, Le Gal G, Lacut K, Le Calvez G, Mansourati J, Mottier D, Abgrall JF and Boschat J: Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: The randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study. J Am Coll Cardiol. 51:256–260. 2008.PubMed/NCBI View Article : Google Scholar
21	Juurlink DN, Gomes T, Ko DT, Szmitko PE, Austin PC, Tu JV, Henry DA, Kopp A and Mamdani MM: A population-based study of the drug interaction between proton pump inhibitors and clopidogrel. CMAJ. 180:713–718. 2009.PubMed/NCBI View Article : Google Scholar
22	Ho PM, Maddox TM, Wang L, Fihn SD, Jesse RL, Peterson ED and Rumsfeld JS: Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA. 301:937–944. 2009.PubMed/NCBI View Article : Google Scholar
23	Depta JP and Bhatt DL: Omeprazole and clopidogrel: Should clinicians be worried? Cleve Clin J Med. 77:113–116. 2010.PubMed/NCBI View Article : Google Scholar
24	Leontiadis GI, Sharma VK and Howden CW: Systematic review and meta-analysis: Enhanced efficacy of proton-pump inhibitor therapy for peptic ulcer bleeding in Asia - a post hoc analysis from the Cochrane Collaboration. Aliment Pharmacol Ther. 21:1055–1061. 2005.PubMed/NCBI View Article : Google Scholar